Aripiprazole for late-life schizophrenia
Jeffrey Rado, Philip G JanicakPsychiatric Clinical Research Center, Rush University Medical Center, Chicago, IL, USAAbstract: Antipsychotics are frequently used in elderly patients to treat a variety of conditions, including schizophrenia. While extensively studied for their impact in younger &s...
Guardado en:
Autores principales: | , |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2010
|
Materias: | |
Acceso en línea: | https://doaj.org/article/82cedea055084d7987558f126be3c376 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Sumario: | Jeffrey Rado, Philip G JanicakPsychiatric Clinical Research Center, Rush University Medical Center, Chicago, IL, USAAbstract: Antipsychotics are frequently used in elderly patients to treat a variety of conditions, including schizophrenia. While extensively studied for their impact in younger ­populations, there is comparatively limited evidence about the effectiveness of these agents in older patients. Further complicating this situation are the high co-morbidity rates (both psychiatric and ­medical) in the elderly; age-related changes in pharmacokinetics leading to a heightened proclivity for adverse effects; and the potential for multiple, clinically relevant drug interactions. With this background in mind, we review diagnostic and treatment-related issues specific to elderly patients suffering from schizophrenia and other psychotic conditions, focusing on the potential role of aripiprazole.Keywords: aripiprazole, schizophrenia, elderly, dopamine partial antagonist |
---|